MMIT Reality Check on Endometriosis (June 2020)

According to our recent payer coverage analysis for endometriosis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access forendometriosis treatments shows that under the pharmacy benefit, about 53% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In April 2020, Myovant Sciences reported positive results in its Phase III studies of once-daily relugolix combination therapy for pain associated with endometriosis.

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image_Diabetes.jpg
November 24

MMIT Reality Check on Type 2 Diabetes (DPP4 and Combo)

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/11/wordpress-featured-image-reality-check-colorectal-cancer.jpg
November 19

MMIT Reality Check on Colorectal Cancer

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/11/wordpress-featured-image-reality-check-cystic-fibrosis.jpg
November 12

MMIT Reality Check on Cystic Fibrosis

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today